Trials / Terminated
TerminatedNCT00937664
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD7762 | solution, intravenous, weekly |
| DRUG | gemcitabine | intravenous, weekly |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2009-07-13
- Last updated
- 2011-02-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00937664. Inclusion in this directory is not an endorsement.